Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Editorial: Rising stars in cancer immunity and immunotherapy 2022.
Goyvaerts C, Engeland CE, Van der Jeught K. Goyvaerts C, et al. Among authors: van der jeught k. Front Immunol. 2023 Nov 7;14:1326374. doi: 10.3389/fimmu.2023.1326374. eCollection 2023. Front Immunol. 2023. PMID: 38022618 Free PMC article. No abstract available.
Targeting the tumor microenvironment to enhance antitumor immune responses.
Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Van der Jeught K, et al. Among authors: van lint s. Oncotarget. 2015 Jan 30;6(3):1359-81. doi: 10.18632/oncotarget.3204. Oncotarget. 2015. PMID: 25682197 Free PMC article. Review.
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells.
Van Lint S, Renmans D, Broos K, Goethals L, Maenhout S, Benteyn D, Goyvaerts C, Du Four S, Van der Jeught K, Bialkowski L, Flamand V, Heirman C, Thielemans K, Breckpot K. Van Lint S, et al. Among authors: van der jeught k. Cancer Immunol Res. 2016 Feb;4(2):146-56. doi: 10.1158/2326-6066.CIR-15-0163. Epub 2015 Dec 11. Cancer Immunol Res. 2016. PMID: 26659303
Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon.
Broos K, Van der Jeught K, Puttemans J, Goyvaerts C, Heirman C, Dewitte H, Verbeke R, Lentacker I, Thielemans K, Breckpot K. Broos K, et al. Among authors: van der jeught k. Mol Ther Nucleic Acids. 2016 Jun 21;5(6):e326. doi: 10.1038/mtna.2016.38. Mol Ther Nucleic Acids. 2016. PMID: 27327138 Free PMC article.
A T Cell-Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy.
Zhou Z, Van der Jeught K, Li Y, Sharma S, Yu T, Moulana I, Liu S, Wan J, Territo PR, Opyrchal M, Zhang X, Wan G, Lu X. Zhou Z, et al. Among authors: van der jeught k. Adv Sci (Weinh). 2023 Aug;10(23):e2300548. doi: 10.1002/advs.202300548. Epub 2023 Jun 4. Adv Sci (Weinh). 2023. PMID: 37271874 Free PMC article.
Targeted immunotherapy for HER2-low breast cancer with 17p loss.
Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, He B, Miller KD, Radovich M, Schneider BP, Pahl A, Zhang X, Lu X. Li Y, et al. Among authors: van der jeught k. Sci Transl Med. 2021 Feb 10;13(580):eabc6894. doi: 10.1126/scitranslmed.abc6894. Sci Transl Med. 2021. PMID: 33568521 Free PMC article.
Adjuvant-Enhanced mRNA Vaccines.
Bialkowski L, Van der Jeught K, Renmans D, van Weijnen A, Heirman C, Keyaerts M, Breckpot K, Thielemans K. Bialkowski L, et al. Among authors: van der jeught k, van weijnen a. Methods Mol Biol. 2017;1499:179-191. doi: 10.1007/978-1-4939-6481-9_11. Methods Mol Biol. 2017. PMID: 27987150
30 results